Personalizing KRAS-Mutant Allele-Specific Therapies.

Titel:: Personalizing KRAS-Mutant Allele-Specific Therapies.
Dokumenttyp:: Journal Article; Comment
Autor(en):: Falcomatà, Chiara; Schneider, Günter; Saur, Dieter
Abstract:: KRASG12R mutations occur almost exclusively in pancreatic ductal adenocarcinoma. The results of a study that reveals specific differences in KRAS downstream signaling and metabolic rewiring of pancreatic cancer cells harboring KRASG12R mutations promise to improve our possibilities to better stratify patients for individualized therapies.See related article by Hobbs et al., p. 104.
Zeitschriftentitel:: Cancer Discov
Jahr:: 2020
Band / Volume:: 10
Heft / Issue:: 1
Seitenangaben Beitrag:: 23-25
Volltext / DOI:: doi:10.1158/2159-8290.CD-19-1261
PubMed:: http://view.ncbi.nlm.nih.gov/pubmed/31919121
Print-ISSN:: 2159-8274
TUM Einrichtung:: II. Medizinische Klinik und Poliklinik (Gastroenterologie); Lehrstuhl für Experimentelle Tumortherapie (Prof. Saur)
BibTeX

Vorkommen: